PRESS RELEASE | Basel, December 18, 2018

Versameb Ltd raises CHF 5.3 million for the development of mRNA therapies in regenerative medicine

Versameb Ltd, a Swiss biopharmaceutical company, announced today the successful closing of a Seed B financing round, bringing the total capital raised to date to CHF 5.3 millions. Versameb Ltd is developing a technology platform for transformative therapies, focusing on regenerative medicine through the local application of messenger ribonucleic acid (mRNA).
“We are very pleased and grateful that our company is enjoying strong support from Swiss and international private investors with both scientific and financial background” commented Prof. Dr. Friedrich Metzger, Versameb’s CEO. He added: “Thanks to our team, we were able to kick-start our operations rapidly and create substantial value in a short period of time. Our technology has the potential to address a broad variety of currently unmet medical needs. I look forward to an exciting discovery and development journey.”
The proceeds will fund the extension of the platform technology, starting of pre-IND activities with the lead program and preclinical activities for additional regenerative medicine indications, and will secure the company’s corporate needs for organizational growth.

Contact for Media Enquiries
Roger Meier, Chairman of the Board

Peter Merian-Strasse 45 | CH-4052 Basel
+41 61 378 87 03 | +41 79 434 52 40
roger.meier@versameb.com

DOWNLOAD PDF
german
english

Versameb has operationally started begin of 2018. We are happy about what we do and to share it with you. If you want to find out more about us, our technology and our products, please contact us under info@versameb.com